Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
28 hedge funds and large institutions have $375M invested in Sinovac Biotech, Ltd in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
833% more funds holding
Funds holding: 3 → 28 (+25)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
12% more capital invested
Capital invested by funds: $336M → $375M (+$39.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$38.2M |
| 2 |
Renaissance Technologies
New York
|
+$849K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$109K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$106K |
| 5 |
Morgan Stanley
New York
|
+$54K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $334M | – | – | – |
|
|
VC
2
Vivo Capital
Palo Alto,
California
| $38.2M | +$38.2M | +5,903,000 | New |
|
|
NAH
3
Neumann Advisory (HK)
Central,
Hong Kong
| $2.04M | – | – | – |
|
|
4
Renaissance Technologies
New York
| $849K | +$849K | +1,312,520 | New |
|
|
5
Wells Fargo
San Francisco,
California
| $109K | +$109K | +16,851 | New |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $106K | +$106K | +16,430 | New |
|
|
7
Morgan Stanley
New York
| $54K | +$54K | +8,344 | New |
|
8
UBS Group
Zurich,
Switzerland
| $14.3K | +$14.3K | +2,213 | New |
|
|
HI
9
Horizon Investments
Charlotte,
North Carolina
| $336 | +$336 | +52 | New |
|
SVA Hedge Fund Activity: Q2 2025 in Review
28 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2025, worth a combined $375M — up 12% from $336M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SVA positions and 0 closed out — a net gain of 26 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $38.2M.
- 28 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2025, up from 3 in Q1 2025.
- Funds reported $375M of Sinovac Biotech, Ltd stock for Q2 2025, up 12% quarter-over-quarter.
- 26 funds opened new Sinovac Biotech, Ltd positions in Q2 2025 and 0 closed out, a net change of +26 holders.
- The largest Sinovac Biotech, Ltd buyer in Q2 2025 was Vivo Capital, an estimated $38.2M added.
Based on aggregated 13F filings for Q2 2025.